{
    "title": "108_hr801",
    "content": "The \"Cloning Prohibition Act of 2003\" prohibits human cloning under the Federal Food, Drug, and Cosmetic Act by adding a new chapter on human cloning. The \"Cloning Prohibition Act of 2003\" prohibits the use of human somatic cell nuclear transfer technology to initiate a pregnancy or ship the product for that purpose. The \"Cloning Prohibition Act of 2003\" prohibits various activities related to cloning and genetic manipulation, including somatic cell nuclear transfer, gene therapy, in vitro fertilization, and animal cloning. Registration is required for individuals intending to perform these activities. Each individual intending to perform human somatic cell nuclear transfer technology must register with the Secretary before starting, providing necessary information and attesting to their qualifications. Individuals must sign a statement declaring awareness of prohibitions and confidentiality rules when registering for human somatic cell nuclear transfer technology research. Disclosure of registration information is limited unless authorized in writing. Nuclear transfer technology research must comply with specific regulations regarding human subjects, including obtaining informed consent from cell donors. In human somatic cell nuclear transfer research, individuals must provide written assurance that the cells will not be used to initiate a pregnancy, in addition to complying with federal regulations on technology use. The research must have written consent from the cell donor, and federal regulations supersede any state laws on human somatic cell nuclear transfer technology. The Cloning Prohibition Act of 2003 prohibits cloning of molecules, DNA, cells, tissues, or organs, with exceptions for existing State or local laws. The section does not establish a private right of action and includes governmental entities in the definition of 'person'. The prohibition expires after 10 years from the enactment date. The Federal Food, Drug, and Cosmetic Act is amended to include penalties for violations of section 1001(a) and failure to register under section 1001(c). Criminal penalties include imprisonment up to 10 years or fines according to title 18, United States Code. Civil penalties for violations of section 301(hh) or section 1001(d) can result in a civil penalty of up to $10,000,000. The Federal Food, Drug, and Cosmetic Act includes penalties for violations of section 301(hh) or section 1001(d), with civil penalties not exceeding $10,000,000 or twice the gross pecuniary gain from the violation. Property derived from or used in such violations is subject to forfeiture to the United States. The Federal Food, Drug, and Cosmetic Act includes penalties for violations, with civil penalties not exceeding $10,000,000 or twice the gross pecuniary gain from the violation. Property derived from or used in such violations is subject to forfeiture to the United States. SEC. 3. STUDY BY INSTITUTE OF MEDICINE. The Secretary of Health and Human Services requests the Institute of Medicine to conduct a study on the biological properties of stem cells from embryos, fetal tissues, and adult tissues, their differences, and potential clinical uses. The Secretary of Health and Human Services requests the Institute of Medicine to study stem cells from embryos, fetal tissues, and adult tissues. If the Institute declines, another entity will conduct the study. A report on the findings must be submitted to specific committees within three years."
}